Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Oncolys BioPharma Inc. <4588> rises as OBP-301 receives FDA fast track designation in U.S.
Oncolys BioPharma Inc. <4588> traded firmly higher. After the close of trading on the 23rd, the company announced that it has received fast track designation from the U.S. Food and Drug Administration (FDA) for a treatment targeting unresectable gastroesophageal cancer using the oncolytic virus OBP-301 in combination with radiation therapy. The fast track designation is a program designed to expedite the review of drugs for serious conditions or diseases with unmet medical needs. OBP-301 received orphan drug designation in the United States in 2020.
Source: MINKABU PRESS
*Translated by generative AI. Click here for the original article.
Related Articles
Crude oil ETFs including NEXT FUNDS NOMURA Crude Oil Long rise as WTI hovers near $97 amid negotiation concerns
STELLA PHARMA CORPORATION rebounds for first time in four days on speculation after Heights Capital disclosed 5.68% stake
YAKULT HONSHA surges to new year-to-date high as U.S. investor Dalton publishes shareholder proposal materials
Hong Kong's Hang Seng Index opens at 25,733.61 on the 24th, down 181.59 points
Umenoyado Brewery debuts at 900 yen, 50% above IPO price
Globalway ranks first in rising buy predictions among individual investors on Minkabu
Sockets Inc. <3634> hits daily limit high on upbeat final profit for previous fiscal year
Foreign exchange summary: Yen trades around 159.70 level, weighed down by finance minister's warning against yen weakness
K.R.S.Corporation rises for first time in three days on subsidiary acquisition in India
Nomura Research Institute,Ltd. <4307> shares remain firm as goodwill impairment at overseas units sparks buying on earnings recovery expectations